Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H7BF
|
|||
| Drug Name |
H3B-8800
|
|||
| Indication | Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 2 | [1] | |
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [2] | ||
| Chronic myelogenous leukaemia [ICD-11: 2A20.0; ICD-10: C92.7; ICD-9: 205.1] | Phase 1 | [2] | ||
| Company |
EisaiWoodcliff Lake, NJH3 Biomedicine Cambridge, MA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Targeting mRNA processing as an anticancer strategy. Nat Rev Drug Discov. 2020 Feb;19(2):112-129. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.